Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Clinical Lung Cancer|November 19, 2019
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNAMarzia Del Re, Iacopo Petrini, Francesca Mazzoni, et al.
Cancers|August 7, 2021
Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic CancerMarzia Del Re, Caterina Vivaldi, Eleonora Rofi, et al.
The Pharmacogenomics Journal|January 19, 2021
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxelCaterina Vivaldi, Stefania Crucitta, Silvia Catanese, et al.
BJU International|May 6, 2019
Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancerMarzia Del Re, Stefania Crucitta, Andrea Sbrana, et al.
British Journal of Cancer|March 7, 2018
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLCMarzia Del Re, Riccardo Marconcini, Giulia Pasquini, et al.
Cancer Immunology, Immunotherapy : CII|December 14, 2020
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLCMarzia Del Re, Federico Cucchiara, Eleonora Rofi, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLCPaola Bordi, Marzia Del Re, Roberta Minari, et al.
Breast Cancer Research and Treatment|July 27, 2019
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patientsMarzia Del Re, Ilaria Bertolini, Stefania Crucitta, et al.
Oncotarget|November 22, 2017
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatmentMarzia Del Re, Paola Bordi, Iacopo Petrini, et al.
JAMA Oncology|November 27, 2018
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical TrialChiara Cremolini, Daniele Rossini, Emanuela Dell'Aquila, et al.
Pageof 3